Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Intangibles (2016 - 2022)

Summit Therapeutics filings provide 9 years of Intangibles readings, the most recent being $8.0 million for Q3 2022.

  • Quarterly Intangibles fell 25.04% to $8.0 million in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $8.0 million through Sep 2022, down 25.04% year-over-year, with the annual reading at $10.4 million for FY2021, 9.69% down from the prior year.
  • Intangibles hit $8.0 million in Q3 2022 for Summit Therapeutics, down from $8.9 million in the prior quarter.
  • Across five years, Intangibles topped out at $21.0 million in Q1 2018 and bottomed at $4.4 million in Q3 2018.
  • Average Intangibles over 5 years is $12.1 million, with a median of $11.5 million recorded in 2020.
  • The largest annual shift saw Intangibles skyrocketed 387.12% in 2018 before it plummeted 35.21% in 2019.
  • Summit Therapeutics' Intangibles stood at $14.1 million in 2018, then fell by 9.0% to $12.8 million in 2019, then fell by 9.99% to $11.5 million in 2020, then fell by 9.69% to $10.4 million in 2021, then fell by 23.53% to $8.0 million in 2022.
  • Per Business Quant, the three most recent readings for SMMT's Intangibles are $8.0 million (Q3 2022), $8.9 million (Q2 2022), and $9.9 million (Q1 2022).